Literature DB >> 19836376

Proteins selectively killing tumor cells.

Mathieu H M Noteborn1.   

Abstract

All human cells have a genetic program that upon activation will cause cell death, named apoptosis. Cancer cells can grow due to unbalances in proliferation, cell cycle regulation and their apoptosis machinery: genomic mutations resulting in non-functional pro-apoptosis proteins or over-expression of anti-apoptosis proteins form the basis of tumor formation. Surprisingly, lessons learned from viruses show that cancer cannot be regarded simply as the opposite of apoptosis. For instance, adenovirus can only transform cells when both its anti- and pro-apoptotic proteins are produced. Oncolytic viruses are known to replicate selectively in tumor cells resulting in cell death. Proteins derived from viruses, i.e. chicken anemia virus (CAV)-derived apoptosis-inducing protein (apoptin), adenovirus early region 4 open reading frame (E4orf4) and parvovirus-H1 derived non-structural protein 1 (NS1), the human alpha-lactalbumin made lethal to tumor cells (HAMLET), which is present in human milk or the human cytokines melanoma differentiation-associated gene-7 (mda-7) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) have all the ability to induce tumor-selective apoptosis. The tumor-selective apoptosis-inducing proteins seem to interact with transforming survival processes, which can become redirected by these proteins into cell death. Transformation-related processes have been identified, which seem to be crucial for the tumor-selectively killing activity of these proteins. For instance, the transformation-related protein phosphatase 2A (PP2A) plays a role in the induction of tumor-selective apoptosis. The proteins mda-7, TRAIL and HAMLET are already successfully tested in first clinical trials. Proteins harboring tumor-selective apoptosis characteristics represent, therefore, a therapeutic potential and a tool for unraveling tumor-related processes. Fundamental molecular and (pre)clinical therapeutic studies of the various tumor-selective apoptosis-inducing proteins apoptin, E4orf4, HAMLET, mda-7, NS1, TRAIL and related proteins will be discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19836376     DOI: 10.1016/j.ejphar.2009.06.068

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Identification of the first human gyrovirus, a virus related to chicken anemia virus.

Authors:  Virginie Sauvage; Justine Cheval; Vincent Foulongne; Meriadeg Ar Gouilh; Kevin Pariente; Jean Claude Manuguerra; Jennifer Richardson; Olivier Dereure; Marc Lecuit; Ana Burguiere; Valérie Caro; Marc Eloit
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Advances in Anticancer Protein Delivery Using Micro-/ Nanoparticles.

Authors:  Wujin Sun; Yue Lu; Zhen Gu
Journal:  Part Part Syst Charact       Date:  2014-10-16       Impact factor: 3.310

Review 3.  Bioactive Compounds in Infant Formula and Their Effects on Infant Nutrition and Health: A Systematic Literature Review.

Authors:  Cristine Couto Almeida; Bianca Figueiredo Mendonça Pereira; Katia Christina Leandro; Marion Pereira Costa; Bernardete Ferraz Spisso; Carlos Adam Conte-Junior
Journal:  Int J Food Sci       Date:  2021-05-14

4.  Human-gyrovirus-Apoptin triggers mitochondrial death pathway--Nur77 is required for apoptosis triggering.

Authors:  Wiem Chaabane; Artur Cieślar-Pobuda; Mohamed El-Gazzah; Mayur V Jain; Joanna Rzeszowska-Wolny; Mehrdad Rafat; Joerg Stetefeld; Saeid Ghavami; Marek J Los
Journal:  Neoplasia       Date:  2014-09       Impact factor: 5.715

5.  Apoptin enhances the oncolytic properties of vaccinia virus and modifies mechanisms of tumor regression.

Authors:  Galina Kochneva; Evgeniy Zonov; Antonina Grazhdantseva; Anastasiya Yunusova; Galina Sibolobova; Evgeniy Popov; Oleg Taranov; Sergei Netesov; Peter Chumakov; Elena Ryabchikova
Journal:  Oncotarget       Date:  2014-11-30

6.  A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.

Authors:  Solmaz Agha Amiri; Soraya Shahhosseini; Najmeh Zarei; Dorsa Khorasanizadeh; Elahe Aminollahi; Faegheh Rezaie; Mehryar Zargari; Mohammad Azizi; Vahid Khalaj
Journal:  AMB Express       Date:  2017-06-02       Impact factor: 3.298

7.  Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo.

Authors:  Xiao Li; Yan Liu; Zhongmei Wen; Chang Li; Huijun Lu; Mingyao Tian; Kuoshi Jin; Lili Sun; Pegn Gao; Encheng Yang; Xiaohong Xu; Shifu Kan; Zhuoyue Wang; Yuhang Wang; Ningyi Jin
Journal:  Mol Cancer       Date:  2010-01-20       Impact factor: 27.401

8.  AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia.

Authors:  V Barbetti; I Tusa; M G Cipolleschi; E Rovida; P Dello Sbarba
Journal:  Cell Death Dis       Date:  2013-03-14       Impact factor: 8.469

9.  Therapeutic anti-tumor effect of exogenous apoptin driven by human survivin gene promoter in a lentiviral construct.

Authors:  Feng Ye; Bo Zhong; Guorong Dan; Fan Jiang; Yan Sai; Jiqing Zhao; Huiqin Sun; Zhongmin Zou
Journal:  Arch Med Sci       Date:  2013-05-28       Impact factor: 3.318

Review 10.  Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development.

Authors:  Mayur V Jain; Anna M Paczulla; Thomas Klonisch; Florence N Dimgba; Sahana B Rao; Karin Roberg; Frank Schweizer; Claudia Lengerke; Padideh Davoodpour; Vivek R Palicharla; Subbareddy Maddika; Marek Łos
Journal:  J Cell Mol Med       Date:  2013-01-10       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.